Two Sigma Investments LP Has $2.13 Million Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Two Sigma Investments LP raised its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 906,767 shares of the company's stock after buying an additional 174,485 shares during the quarter. Two Sigma Investments LP owned approximately 0.34% of Autolus Therapeutics worth $2,131,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Virtus ETF Advisers LLC raised its position in shares of Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares during the period. Daiwa Securities Group Inc. increased its stake in Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $26,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Autolus Therapeutics by 21.2% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,411 shares of the company's stock valued at $194,000 after buying an additional 14,432 shares in the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Up 8.4%

NASDAQ AUTL traded up $0.16 on Tuesday, reaching $2.07. The stock had a trading volume of 5,900,970 shares, compared to its average volume of 1,527,177. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The business has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.99. The company has a market capitalization of $550.91 million, a price-to-earnings ratio of -1.71 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. On average, analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on AUTL shares. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Truist Financial decreased their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.